Kornimate/medical-research-clean huggingface dataset:
electrocardiographic changes among epileptic and non epileptic seizures in children at sohag university hospital

Conditions: Seizures

Summary: epilepsy is a chronic disease triggered by increased impulsiveness of nerve cells in the brain and may require a lifelong treatment. epilepsy is confirmed by two or more unprovoked seizures in more than 24 hours. febrile convulsion is another type of seizure occurring due to fever over 38 °c without a history of convulsion, cns infection, electrolyte imbalance, metabolic disorder, intoxication, and trauma. unlike epileptic seizures, there are non-epileptic seizures such as breath holding spells that affect children's behaviors and often look like epileptic seizures. qt parameters elongation show the danger of dysrhythmia and unexpected sicknesses such as cardiomyopathy, mitral valve prolapse, ischemic coronary illness, and kidney disorders. many investigators have reported changes in qt parameters in various diseases such as diabetes mellitus, celiac disease, thalassemia , epilepsy ,breath holding spells and febrile seizure.


Eligibility criteria:
inclusion criteria: * children with drug resistant epilepsy. * febrile seizures. * age of 1 year to 12 years. exclusion criteria: * age below 1 year and above 12 years * children with convulsion secondary cns infection , encephalitis, encephalopathy , toxic and metabolic problem
the effect of vildagliptin based treatment versus sulfonylurea on glycemic variability, oxidative stress, glp-1, and endothelial function in patients with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: the effect of vildagliptin based treatment versus sulfonylurea based treatment on glycemic variability, oxidative stress, and endothelial function in patients with type 2 diabetes.

recently, improved understanding of the incretin effect on the pathophysiology of type 2 diabetes has led to development of new agent for hypoglycemic therapy. vildagliptin is a potent and highly selective dipeptidyl peptidase-4 (dpp-4) inhibitor that augments the active glucagon-like peptide(glp)-1 concentration, increases insulin secretion and improves glucose tolerance. vildagliptin has a similar glucose lowering effect, but lower hypoglycemic events, as compared to glimepiride. vildagliptin could improve not only the mean glycemic control but also 24 hour glycemic fluctuation by restoring the physiologic pattern of insulin and glucagon secretion. furthermore, decreased postprandial glycemic excursion might reduce the oxidative stress markers and improve endothelial dysfunction. those effects might be amplified in asian patients because of prominent early phase insulin secretory defects accompanied with relatively less degree of insulin resistance. in addition, glp-1 and glp-1 analogues exert direct beneficial effects on endothelium-dependent vasodilatation. therefore dpp-4 inhibitors may directly improve endothelial dysfunction. based on this assumption, this research will focus on the effect of vildagliptin on glycemic variability, oxidative stress markers and endothelial cell function compared to long acting sulfonylurea glimepiride in type 2 diabetic patients with inadequate glycemic control on metformin.

Eligibility criteria:
inclusion criteria: * type 2 diabetic patients with hemoglobin a1c levels within the range 7% - 10%

Keywords: glucose variability oxidative stress endothelial cell function
determining serum and urinary levels of mirna 192 and mirna 25 in patients with and without type 2 diabetes.

Conditions: Diabetic Kidney Disease; Type2 Diabetes

Summary: diabetes kidney disease (dkd) is the leading cause of end stage renal disease (esrd) in western countries and its incidence is worryingly increasing worldwide. cardiovascular disease shows a continuous relationship with declining of renal function in type 2 diabetes patients. moreover, there is a strong evidence of all-cause mortality risk excess even in patients with early stages kidney disease. microrna (mirna) are small non-coding rna molecules, containing 21-25 nucleotides, that modulate post-transcriptional gene expressions. in the past years many human mirnas involved in the pathogenesis of renal disease have been discovered, such as mir-192, mir-194, mir-204 and mir-25. among these, mir-192 and mir-25, are receiving greater attention while it seems that they play a role in glomerulosclerosis and renal fibrosis. however too few data are available in large publish trials among patients with renal impairment and the role of serum and urinary levels of mir-192 and mir-25 in people with preserved renal function remain unclear. to evaluate the association between serum and urinary expression of mir-192 and mir-25 and renal function (according to different extent of renal impairment) in patients with or without type 2 diabetes.

the day of the study patients undergo a routine clinical evaluation. whole blood samples are collected from an antecubital vein to assess serum/plasma aliquots of 200 μl each (frozen at -80°c until required for quantitation) for evaluation of biochemical parameters (fasting glucose, hba1c, lipid profile, serum creatinine, uric acid, electrolytes, liver function enzymes, albumin) and determination of serum mir-192 and mir-25. two urine samples will be also collected to assess aliquots of 200 μl each (frozen at -80°c until required for quantitation) for determination of albumin:creatinine ratio and urine expression of mir-192 and mir-25.

Eligibility criteria:
inclusion criteria (group 1, diabetic patients): * age ≥ 18 years and ≤ 75 years * male or female patients with type 2 diabetes treated with life style modification only or any oad or insulin * bmi ≥ 20 e ≤ 40 kg/m2 * patients able to consent exclusion criteria (group 1, diabetic patients): * personal history of current or previous cancer or chemotherapy in the past 5 years * personal history of alcohol and/or drugs abuse in the previous 3 months * pregnancy inclusion criteria (group 2, non-diabetic patients): * age ≥ 18 years and ≤ 75 years * bmi ≥ 20 e ≤ 40 kg/m2 * patients able to consent exclusion criteria (group 2, non-diabetic patients): * diagnosis of type 2 or type 1 diabetes * personal history of current or previous cancer or chemotherapy in the past 5 years * personal history of alcohol and/or drugs abuse in the previous 3 months * pregnancy

Keywords: dkd mirna-25 mirna-192
emtricitabine for naive child chinese chronic hepatitis b patients

Conditions: Hepatitis B, Chronic

Summary: this study evaluates generic emtricitabine(ftc) in chinese naive children chronic hepatitis b patients. single group of child patients were enrolled, which include hbeag positive and negative chronic hepatitis b(chb)group.

generic emtricitabine(ftc) has been approved for treatment of naive chronic hepatitis b(chb) patients in china. yet data are limited for this agent in children paitients. the investigators design this trial to test the effect of ftc in chinese children chb which including naive hbeag positive and negative chb patients.

Eligibility criteria:
inclusion criteria: * children with body weight ≥ 33 kg and who can swallow entire emtricitabine capsle(200mg) * hbsag positive for more than 6 months * hbeag positive patients: hbv dna ≥ 5log10 copies/ml * hbeag positive patients: alt≥2×uln;or liver biopsy g≥2;or liver biopsy s ≥2;or liver biopsy knodell hai ≥ 4 * hbeag negative patients: hbv dna ≥ 4log10 copies/ml * hbeag positive patients: alt≥2×uln;or liver biopsy g≥2;or liver biopsy s ≥2;or liver biopsy knodell hai ≥ 4 * nucleoside/nucleotide naive patients exclusion criteria: * - diagnosed hcc with afp and ultrasound, ct or mri * creatine \>130μmol/l or ccr \< 70ml/min * hemoglobin \<100g/l * neutrophils \<1.5e+9/l * plt\<80e+9/l * coinfected with hav,hev,hcv,hdv or hiv * ana \> 1:100 * uncontrolled cardiovascular diseases, kidney diseases,lung diseases, neurological diseases, digestive diseases,metabolic disorders, immune-compromised diseases or cancer * drug abuse or alcohol addiction * previous history of taking agents of lamivudine, adefovir, tenofovir entecavir or telbivudine * long-term use of immunosuppressor or immunomodulator 6 months before enrollment to this trial * underwent liver transplantation or liver transplantation in schedule * allergic to nucleoside or nucleotide analogues * pregnancy or in breastfeeding

Keywords: hepatitis b, chronic emtricitabine child
assessment of depression, anxiety and adhd among children and adolescents with congenital heart disease.

Conditions: Assessment of Depression, Anxiety and ADHD Among Children and Adolescents with Congenital Heart Disease

Summary: congenital heart disease (chd) is the most common birth defect, affecting ∼1% of all live births.the spectrum of chd is wide, ranging from simple (not requiring immediate or possibly any surgical intervention) to severe or complex (typically defined as chd requiring surgical intervention within the first month to year of life).

although overall mortality has improved, most notably in those with complex chd, many surgical and medical procedures are palliative, and these patients often require multiple interventions throughout their lifetime. increased chd survival is now resulting in a continually growing population of adolescents and adults with chd; this has drawn more attention to the noncardiac comorbidities, including overall mental health, of patients with chd.there are multiple psychological theories that can potentially explain some of the mental health disorders seen in patients with chd, such as stressful life events and sociocultural impacts (eg, parenting style).cognitive models, including learned helplessness and negative information processing, may also contribute to the mental health of children with chd, who often spend significant amounts of time in the hospital and undergo cardiac procedures and surgeries. the presence of underlying genetic syndromes, parental mental health disorders, cardiopulmonary bypass, prematurity, and prolonged hospitalizations are factors that increase the risk of neurodevelopmental disabilities (ndds) and likely contribute to anxiety, depression, and attention-deficit/hyperactivity disorder (adhd) in adolescents and adults with complex chd.

Eligibility criteria:
inclusion criteria: * childern age from 6 to less than 18 * childern with simple and complex chd * in patient and out patient childern * preoperative and postoperative patient exclusion criteria: * patient indicated for icu * patient with critical arrythmias * caregiver refuse to participate in the study

Keywords: congenital heart disease assessment of depression, anxiety and adhd
vending labeling sales and intercepts study

Conditions: Food Preferences; Obesity; Weight Gain

Summary: the aim of this study is to compare the impact of 4 different types of front of package (fop) food and beverage messages: 1) green labels on healthy foods, 2) red/yellow/green labels on less healthy/moderately healthy/healthy foods, 3) physical activity calorie equivalent labels, and 4) posters reminding consumers of the sweetened beverage tax on consumers' beverage and snack selections.

this project involves a randomized field experiment. the investigators worked with the vending contractor for the city of philadelphia to randomize vending machine locations (covering \~260 beverage and snack machines) to one of the four different message conditions: 1) single green traffic light labels (on healthy foods); 2) multiple traffic light labels (red traffic light labels applied to less healthy foods, yellow applied to moderately healthy foods, and green on healthy foods); 3) physical activity labels (calorie content displayed in terms of physical activity equivalents); 4) posters reminding consumers of the philadelphia sweetened beverage tax and encouraging healthier choices. the city's vending machine contractors provided monthly aggregated sales data from each machine for analysis. customer intercepts were also collected at the point of sale, after customers completed their purchase, to evaluate factors that moderate message influence. they were asked to answer questions about their perceptions of the different labels.

Eligibility criteria:
sales data include all purchases at the machine regardless of customer demographics. customer purchase assessment data were collected from: inclusion criteria: * any person aged 18 or older making a purchase from the vending machines included in this intervention will be asked to participate in this study. exclusion criteria: * people who indicate they have already taken the survey are not eligible to take the survey again.

Keywords: food labeling sugar-sweetened beverages eating drinking choice behavior
effect of exercise training on the function of the high density lipoprotein (hdl)-cholesterol, endothelial function and endothelial progenitor cells in patients with metabolic syndrome(hermet-study)

Conditions: Metabolic Syndrome X

Summary: the purpose of the present study is to characterize the quality of hdl-cholesterol in patients with metabolic syndrome and reduced blood hdl-cholesterol levels and to examine the effect of exercise training on the vasculoprotective effects of hdl-cholesterol in these patients. additionally the investigators aim to investigate the endothelial function, oxidative stress and the regenerative capacity of the endothelial progenitor cells in patients with metabolic syndrome and the changes dependent on physical activity of patients.


Eligibility criteria:
inclusion criteria: * reduced hdl-cholesterol levels in blood: \< 40 mg/dl (1.03 mmol/l) in male, \< 50 mg/dl (1.29 mmol/l) in female * plus two of the following criteria: * elevated waist circumference: ≥ 102 cm (≥ 40 inches) in men or ≥ 88 cm (≥ 35 inches) in women * elevated triglycerides: ≥ 150 mg/dl (1.7 mmol/l * elevated blood pressure: ≥ 130 mmhg systolic blood pressure or ≥ 80 mmhg * diastolic blood pressure or anti-hypertensive treatment * elevated fasting glucose: ≥ 100 mg/dl or on drug treatment for elevated fasting glucose exclusion criteria: * acute coronary syndrome * unstable angina pectoris * myocardial infarction during the last 8 weeks * therapy with niacin * active infections * ventricular arrhythmias * systolic blood pressure \> 160 mmhg or diastolic blood pressure \> 95 mmhg * cancer * pregnancy, lactation * alcoholism

Keywords: metabolic syndrome hdl-cholesterol epc endothelial function reduced blood hdl-cholesterol level
clinical efficacy of a non-invasive measure of intracranial pressure

Conditions: Intracranial Pathology; Intracranial Hypertension

Summary: this study is designed to evaluate the accuracy of a non-invasive method phase-contrast magnetic resonance imaging (mr-icp) for assessing intracranial pressure (phase 1). to perform second phase contrast imaging to evaluate the patency and flow of ventricular catheters after mr-icp imaging (phase 2).

the study will be divided into 2 phases. in phase 1, patients with an intracranial pressure monitor will be recruited to the study, while in phase 2, patients with shunts or cerebral spinal fluid (csf) access devices (ommaya, reservoir, etc.) will be eligible for the study. two separate groups of patients will be recruited to each phase of the study. each phase of the study will involve mr-icps. the mr-icp is an extra 5-10 minute sequence at the end of a mri that assesses the pressure in the head. the mri will take scans of the brain during different phases of the cardiac cycle and will assess the volume changes while the patient is lying flat. the pressure in the head will be estimated based on these calculations. this estimate will be compared to the pressure in the head as determined by the icp monitor.

Eligibility criteria:
inclusion criteria: * patients referred for a mri by attendings in the department of neurological surgery at the university of miam with intracranial pathology with external ventricular drains (evds) or intracranial bolts placed for hydrocephalus or intracranial hypertension. bolts must be placed prior to enrollment in the study to avoid any alterations in standard procedure * all pathological entities that produce intracranial hypertension will be included (trauma, tumor, vascular, infectious, inflammatory, etc). * patients must undergo a mri for another clinically indicated reason (diagnosis, surveillance, cervical mri clearance, prognosis, etc). * english and spanish-speaking patients exclusion criteria: * unable to obtain mri due to prior implants, metallic material, inability to sit still * refractory intracranial hypertension (not controlled with medications, surgery, or evd) * unable to obtain informed consent

Keywords: non-invasive magnetic resonance imaging ventricular catheters
rivaroxaban in left ventricular thrombus

Conditions: Acute Coronary Syndrome; Left Ventricular Thrombus

Summary: the left ventricular (lv) thrombus is an important complication of myocardial infarction (mi) and vitamin k antagonist (vka) is the current recommended management therapy for these patients. however, lack of regular international normalized ratio (inr) monitoring, drug, and food interaction may leads to increased risk of over or under anticoagulation consequently compromising the effectiveness of the therapy. hence, due to benefits like predictable dosing and lack of need for regular monitoring, use of non-vitamin k antagonist oral anticoagulants (noacs) for these patients is increasing among cardiologists. however, clinical data for the justified use of noacs in lv thrombus (lvt) are lacking and remained a point of debate among the cardiologists. a recently published randomized control trial (rct) by abdelnabi m et al. namely the no-lvt trial, had established the safety of rivaroxaban therapy in patient with post myocardial infarction (mi) lv thrombus along with promising efficacy. however, sample size of the study (n=79; 39 in rivaroxaban and 40 warfarin) was not sufficiently high enough to conclude efficacy of rivaroxaban in these patients. therefore, this open label rct is designed with the primary objective to evaluate the efficacy of rivaroxaban in resolution of post mi lv thrombus as compared to standard warfarin therapy at the interval of 1 month and 3 months to test the hypothesis that rivaroxaban is safe and non-inferior in preventing thromboembolic and major bleeding events in these patients.


Eligibility criteria:
inclusion criteria: * patients of acute coronary syndrome with lv thrombus * hemodynamically stable * willing to participate exclusion criteria: * prior history of cardiomyopathy * anticoagulant contraindications * prior history of stroke with residual neurological deficit * valvular atrial fibrilation * pregnancy * mentally retarded * deranged liver function tests (lfts) * creatinine clearance \<50 ml
requests for euthanasia and assisted suicide

Conditions: Suicide, Assisted

Summary: the study epidesa2 identifies all explicit requests for euthanasia or assisted suicide expressed by the person him/herself, regardless of which professional is asked and regardless of where the request is made (primary care, health institutions, medico-social institutions including nursing home care or at home) in the burgundy-franche-comté region during six months.


Eligibility criteria:
inclusion criteria: any adult : * living at home, or in medico-social institutions or hospitalized in primary care or health institutions of burgundy-franche-comté, * at the end of life due to advanced stage disease or a major change in the state of health of an elderly person, * who expressed an explicit request for euthanasia or assisted suicide, * who expressed their no objection to the collection of their datas, * who are covered by the french social security system. exclusion criteria: * they are underage * the request was expressed by another person * the request is not an explicit request * the request appears in the context of a situation other than illness or a general change in state of health * the patient is mentally confused

Keywords: palliative care euthanasia epidemiologic studies
carbetocin on myocardial repolarization dynamics in obstetrics study

Conditions: Cardiac Arrythmias

Summary: relationship between carbetocin dose on transmural dispersion of repolarization (tdr).

carbetocin is a uterotonic used to prevent postpartum hemorrhage. although it has been proven to be completely safe, little is known about its effects on the electrical activity of the heart. the investigators aim to determine its effect on myocardial repolarization dynamics

Eligibility criteria:
inclusion criteria: * pregnant patients ≥ 36 weeks gestation, for elective cesarean delivery under neuraxial anesthesia * american society of anesthesiologists (asa) class 2 * patients ≥ 19 years of age exclusion criteria: * long qt syndrome * cardiac disease or rhythm abnormalities * family history of long qt syndrome or abnormal cardiac conduction * currently taking medication that is known to prolong the qt interval * women who are high risk for uterine atony as outlined in sogc * known allergic reaction or hypersensitivity to carbetocin or any other oxytocin homologue * patients who are unable to give informed consent because of a language barrier as the study team only speaks english and will be unable to complete consent process and study procedure appropriately.

Keywords: carbetocin myocardial repolarization
self tonometry and transfer of glaucoma patients' data for improving the supply situation

Conditions: Glaucoma; Intraocular Pressure; Patient Empowerment; Telemedicine

Summary: the salus project is developing a new form of care, the application of self-tonometry by the patient itself, and an accompanying electronic case file connecting clinics, doctor's offices and patients.

the salus project is developing an outpatient, intersectoral form of care in which patients measure their intraocular pressure in their home environment with a so-called self-tonometer. the measured intraocular pressure values are incorporated into daily pressure profiles, which can be viewed via an electronic case file together with further examination data both by the treating ophthalmologists in the doctor's offices and clinics and by the patients. the new form of care not only supports the telemedical networking of doctors but also increases the compliance by involving the patient in the entire course of the illness.

Eligibility criteria:
inclusion criteria: * requirement of a stationary day and night measurement * statutory health insurance * verified and suspicion of glaucoma diagnosis with suspicion of pressure variations and peaks or not attained target pressure or suspicion of glaucoma progression (h40.1, h40.2 und h42.-) * willingness for therapy in one of the participating clinics * adequate german language skills * signed and dated informed consent for study participation and data transfer * legal capacity of the insurant to agree to the study participation exclusion criteria: * patients outside the catchment area of the participating clinics * covering illnesses in psychiatry, neurology or other indications (e.g. impairment of independence) which make self-tonometry impossible * strong communication barriers that do not allow the instruction to carry out the intervention * unclear legal capacity of the potential study participants